奈非那韦治疗失败后使用茚地那韦、依非韦伦和阿德福韦进行治疗。

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

作者信息

Saah Alfred J, Haas David W, DiNubile Mark J, Chen Joshua, Holder Daniel J, Rhodes Rand R, Shivaprakash Malathi, Bakshi Kalpana K, Danovich Robert M, Graham Donald J, Condra Jon H

机构信息

Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

J Infect Dis. 2003 Apr 1;187(7):1157-62. doi: 10.1086/368287. Epub 2003 Mar 19.

DOI:10.1086/368287

PMID:12660932

Abstract

A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.

摘要

开展了一项前瞻性开放标签研究，以评估茚地那韦、依非韦伦和阿德福韦对接受含奈非那韦方案治疗时出现病毒反弹的人类免疫缺陷病毒（HIV）感染患者的疗效，确定蛋白酶基因型是否会影响挽救治疗方案的结果。对29例奈非那韦治疗失败患者进行基因分型，结果显示17例（59%）为D30N，11例（38%）为L90M。携带D30N病毒的患者中，56%在第48周时病毒RNA拷贝数抑制至<400/mL，而携带L90M病毒的患者中这一比例为18%。